CONSENSUS: COVID-19 vaccine responses after extended immunisation schedules

Project summary:

The UK Health Security Agency (UKHSA) is undertaking this audit to assess the antibody levels offered by the extended 12-week schedule, compared to a 2 to 3 week interval, and the booster programme in people aged 50 years and over. Participants will provide blood samples at specific time points to measure the antibodies provided by the COVID-19 vaccine against the novel coronavirus, SARS-CoV-2. Some participants will also provide extra blood at some of the visits for additional cellular immunity tests. Data from the audit will provide important information about the level of immunity provided by the primary vaccine and booster doses.

Lead institution:

UK Health Security Agency

Vaccine type:

Pfizer